Abstract
The search for pharmaceutical treatment for COVID-19 has been progressive. Currently approved medicines include therapeutic antibodies and antiviral drugs. However, the effectiveness of current antiviral drugs is far from satisfactory, which suggests the necessity for improvement. In this research, we selected the non-structural protein complex Nsp16-Nsp10, which is responsible for methylating SARS-CoV-2’s RNA, as a drug target. With computer-aided drug development technology, we screened two potential drugs either by inhibiting the SAM catalytic pocket on the complex or inhibiting the binding between Nsp16 and Nsp10 from preventing the Nsp16-Nsp10 complex helping SARS-CoV-2 duplicate, and that will work in COVID-19 treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
